ID   MCF-7/164R-5
AC   CVCL_1D38
SY   MCF7/164R-5; MCF-7/164(R)-5; 164R-5
DR   Wikidata; Q54904340
DR   Ximbio; 152102
RX   PubMed=7759159;
RX   PubMed=16172194;
RX   PubMed=25362855;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from metastatic site: Pleural effusion.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1D47 ! MCF-7/S0.5
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 20-05-21; Version: 12
//
RX   PubMed=7759159; DOI=10.1002/ijc.2910610417;
RA   Lykkesfeldt A.E., Larsen S.S., Briand P.;
RT   "Human breast cancer cell lines resistant to pure anti-estrogens are
RT   sensitive to tamoxifen treatment.";
RL   Int. J. Cancer 61:529-534(1995).
//
RX   PubMed=16172194; DOI=10.1677/erc.1.00946;
RA   Frogne T., Jepsen J.S., Larsen S.S., Fog C.K., Brockdorff B.L.,
RA   Lykkesfeldt A.E.;
RT   "Antiestrogen-resistant human breast cancer cells require activated
RT   protein kinase B/Akt for growth.";
RL   Endocr. Relat. Cancer 12:599-614(2005).
//
RX   PubMed=25362855; DOI=10.1038/onc.2014.351;
RA   Thrane S., Pedersen A.M., Thomsen M.B.H., Kirkegaard T.,
RA   Rasmussen B.B., Duun-Henriksen A.K., Laenkholm A.-V., Bak M.,
RA   Lykkesfeldt A.E., Yde C.W.;
RT   "A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as
RT   novel treatment targets in antiestrogen-resistant breast cancer
RT   cells.";
RL   Oncogene 34:4199-4210(2015).
//